Analysts expect over 2021 rising revenue arGEN-X

Tomorrow the Belgian arGEN-X will report its past quarters results. Over the current book year the company from Breda's total revenue could be around 255.99 million euros (consensus estimates). This is quite more than 2021's revenue of 36.43 million euros.

Historical revenues and results arGEN-X plus estimates 2021

The analysts expect for 2021 a net loss of 720 million euros. The majority of the analysts expects for this year a loss per share of 14.64 euros. With this the price/earnings-ratio is -17.15.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals an attractive 2.28 percent.

Most recent target prices around 299 euros

arGEN-X 's market capitalization is around 10.74 billion euros. 14

Historical stock prices arGEN-X from 2007 till 2021

At 10.42 the stock trades 0.24 percent higher at 251.1 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.